Clearside Biomedical (CLSD) announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema, UME. XIPERE is approved for use in the United States, Canada, Australia, and Singapore and under regulatory review in China.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Snowflake initiated, Chipotle upgraded: Wall Street’s top analyst calls
- Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright
- Clearside Biomedical downgraded to Neutral from Buy at Chardan
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties